Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | S100A4 | P26447 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23255814 | 0.85 | HSPB1 (0.49) | TDP1LMNAHTTMEN1KMT2A | |
| SCHEMBL38657150 | 0.81 | TDP1 (0.64) | TDP1LMNAHTTMEN1KMT2A | |
| SCHEMBL1027041 | 0.81 | TDP1 (0.64) | TDP1LMNAHTTMEN1KMT2A | |
| SCHEMBL23255809 | 0.79 | MEN1 (0.47) | TDP1LMNAHTTMEN1KMT2A | |
| SCHEMBL4962536 | 0.77 | MAPT (0.55) | TDP1LMNAHTTMEN1KMT2A | |
| SCHEMBL28003798 | 0.77 | MEN1 (0.46) | TDP1LMNAHTTMEN1KMT2A | |
| SCHEMBL3030993 | 0.76 | LMNA (0.56) | TDP1LMNAHTTMEN1KMT2A | |
| SCHEMBL12573344 | 0.75 | SNCA (0.47) | TDP1LMNAHTTMEN1KMT2A | |
| SCHEMBL1025344 | 0.74 | PTGDR2 (0.64) | TDP1LMNAHTTMEN1KMT2A | |
| SCHEMBL5099603 | 0.74 | MAPT (0.48) | TDP1LMNAHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695179-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, BRD3, BRDT | TDP1 1357/4885LMNA 1402/4885HTT 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.